IL6 and diffuse large B-cell lymphoma: We have found that IL-6 induces chemotherapy resistance for rituximab (anti-CD20 monoclonal antibody), protects lymphoma cells from spontaneous and drug-induced apoptosis, and eventually promotes the growth of DLBCL through JAK/STAT3 and PI3K/Akt pathway [7, 11].